SWOG clinical trial number
SWOG-9450
Prostate Cancer Intervention Versus Observation Trial
Closed
Phase
Published
Abbreviated Title
Local Prostate
Activated
05/01/1995
Closed
11/30/2001
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Age < /= 75 yrs; Clinically localized tissue documented adenoca. of the prostate, (T1 a,b,c, - T2 a,b,c, NX, M0); Diagnosis of CAP within previous 6 mo; PSA < 50 ng/ml,(if currently taking finasteride, PSA < 25 ng/ml); no prior pelvic RT, chemo, anti-androgen or androgen deprivation therapy except 5-alpha-reductase inhibitors; no prior surg. other than TURP/TUIP/dilation/simple prostatectomy; no current estrogen or androgen blocking therapy; no evidence of metastatic dz., no significant medical conditions or high surgical risks (MI within last 6 mo, unstable angina, severe CHF pulmonary or hepatic dz, see p. 31 of the Manual of Operations for complete description).
Publication Information Expand/Collapse
2012
Prostate Cancer - uncertainty and a way forward
PMid: PMID22808963 | PMC number: n/a (commentary)
1997
The prostate cancer intervention versus observation trial (PIVOT).
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase